Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Claya vs Revive Meds

Claya
Graded #264

Higher grade

vs+5.899999999999999
Revive Meds
Graded #404

Lower grade

The verdict

Claya takes it — 62.8/100 to 56.9/100.

Claya grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Claya is a direct-to-consumer telehealth platform offering compounded semaglutide and tirzepatide in both injectable and oral-tablet forms — a wider format range than most competitors.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueClaya +21
42
21
Dose & formulationClaya +11
75
64
Clinical oversightClaya +2
82
80
Labs & monitoringClaya +1
53
52
FulfillmentRevive Meds +23
67
90
Contract termsClaya +8
61
53
Claya · left barRevive Meds · right bar

The numbers

MetricClayaRevive Meds
WeighScore62.8/10056.9/100
GradeCC
Scorecard rank#264#404
Semaglutide$299/mo (compounded)$369/mo (starting dose, compounded)
Tirzepatide$299/mo (compounded)$459/mo (starting dose, compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Claya

Graded #264 · C

Strengths

  • Two named licensed clinicians (Habashy, NMD MS and Barber, MD PhD) — rare transparency for compounded GLP-1
  • Two named pharmacy partners with full addresses (RedRock, UT and Healthware, KY)
  • Both injectable and oral-tablet forms offered for semaglutide and tirzepatide
  • Weight-loss money-back guarantee published on the homepage
  • Free expedited shipping included in the monthly price

Where it loses points

  • States-served list not disclosed — you must check at checkout
  • LegitScript certification status not displayed
  • Corporate legal entity not disclosed on the site or privacy policy
  • Oral compounded tablets have weaker efficacy data than injectable semaglutide
  • Intro pricing is higher at refill ($299), erasing the first-month advantage
Revive Meds

Graded #404 · C

Strengths

  • Offers both compounded semaglutide and dual-agonist tirzepatide, each combined with vitamin B12 (cyanocobalamin) in a single injection
  • Pay-per-order model with no subscription, sign-up fees, or long-term commitment, and free shipping on every order
  • Names its six 503A compounding pharmacies and two prescribing physicians, which is unusually transparent on fulfillment
  • Available in all 50 states and HSA/FSA eligible through a Medical Necessity Letter
  • Prepaying 3 to 12 months cuts the effective cost to as low as $202/mo (semaglutide) or $300/mo (tirzepatide)

Where it loses points

  • Month-to-month pricing is steep: $369/mo semaglutide and $459/mo tirzepatide unless you prepay several months
  • No public price list; pricing appears only after you complete a full health intake and create an account
  • Not LegitScript-certified (no seal displayed on the site)
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard